中国结核病疫苗研发现状及展望  

Landscape and prospect of tuberculosis vaccine research and development in China

作　　者：张梦娴 王倪[2] 黄飞[2] 周丽平[1] 赵雁林[2] Zhang Mengxian;Wang Ni;Huang Fei;Zhou Liping;Zhao Yanlin(Institute for Tuberculosis Control and Prevention,Hubei Provincial Center for Disease Control and Prevention,Wuhan 430079,China;National Center for Tuberculosis Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China)

机构地区：[1]湖北省疾病预防控制中心结核病防治研究所,武汉430079 [2]中国疾病预防控制中心结核病预防控制中心,北京102206

出　　处：《中国防痨杂志》2023年第2期125-129,共5页Chinese Journal of Antituberculosis

基　　金：中国结核病疫苗研发能力和现状研究(INV-030929)。

摘　　要：卡介苗是目前唯一在市场上使用的结核病疫苗,主要可以减少儿童结核性脑膜炎和播散性结核病的发生,但是对青少年和成年人的保护效果有限。为实现“终结结核病流行目标”,研发和推广针对全年龄段、有效的新型结核病疫苗至关重要。鼓励研发新型结核病疫苗、参与国际多中心临床试验,有助于激发内部活力、缩短结核病疫苗研发周期、加快疫苗上市和推广速度。作者梳理了中国进入临床研究阶段的结核病疫苗现状、相关支持性政策和国际多中心临床试验的基本要求等,并对未来结核病疫苗的研发进行了展望。BCG is currently only available vaccine for tuberculosis(TB)at global level.It can mainly reduce the occurrence of tuberculous meningitis and disseminated tuberculosis in children,however,the protection effect on adolescents and adults is limited.In order to achieve“The End TB Strategy”,it is essential to research and develop novel tuberculosis vaccines that are effective for all ages.Encouraging research and development of new tuberculosis vaccines and participating in multi-regional clinical trials,which will help stimulate internal vitality,shorten the research and development cycle of TB vaccine,and accelerate the marketing and promotion speed.The author sorted out the current status of TB vaccine which are in clinic trial,the relevant supportive policies,the basic requirements of the multi-regional clinical trials and TB vaccine landscape.

关 键 词：结核 疫苗 研究 综述文献(主题) 

分 类 号：R52[医药卫生—内科学] R97[医药卫生—临床医学] R8